Success Metrics

Completion Rate

0%(0/1)

Active Trials

1(33%)

Terminated

1(33%)

Phase Distribution

Ph phase_1

33%

Ph phase_2

33%

Ph phase_3

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 2Efficacy & side effects

1(33.3%)

Phase 3Large-scale testing

1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Terminated(1)

Detailed Status

Not yet recruiting1

Terminated1

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

0.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (33.3%)

Phase 21 (33.3%)

Phase 31 (33.3%)

Trials by Status

not_yet_recruiting133%

terminated133%

recruiting133%

Recent Activity

1 active trials

Showing 3 of 3

recruitingphase_3

Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome

NCT07168434

not_yet_recruitingphase_2

Safety and Efficacy of Isomyosamine in Reducing Inflammation and Treating Muscle Loss in Older Adults After Hip or Thigh Bone Fractures

NCT06942182

terminatedphase_1

Study to Assess Tolerability, Safety and Pharmacokinetics of a New Drug

NCT01702675

Clinical Trials (3)

Showing 3 of 3 trials

NCT07168434Phase 3

Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome

Recruiting

NCT06942182Phase 2

Safety and Efficacy of Isomyosamine in Reducing Inflammation and Treating Muscle Loss in Older Adults After Hip or Thigh Bone Fractures

Not Yet Recruiting

NCT01702675Phase 1

Study to Assess Tolerability, Safety and Pharmacokinetics of a New Drug

Terminated

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3